Paralel Advisors LLC Invests $5.29 Million in Humana Inc. $HUM

Key Points

• Paralel Advisors LLC purchased a new $5.29 million stake in Humana during the second quarter, acquiring 13,322 shares. Institutional investors collectively own 92.38% of the company.
• Humana’s latest quarterly results exceeded expectations, with EPS of $7.61 versus the $7.27 consensus estimate and revenue of $40.89 billion, up 26.2% year over year.
• Analyst sentiment is mixed: 14 analysts rate the stock Buy, 15 Hold and one Sell, resulting in a consensus Hold rating and a $395.22 target price versus the reported share price of $380.48.

Paralel Advisors LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 13,322 shares of the insurance provider's stock, valued at approximately $5,292,000. Humana comprises approximately 0.2% of Paralel Advisors LLC's holdings, making the stock its 23rd biggest position.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in Humana by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider's stock worth $3,652,890,000 after acquiring an additional 106,030 shares in the last quarter. BlackRock Inc. bought a new position in shares of Humana during the 2nd quarter valued at $4,138,160,000. Capital International Investors lifted its stake in shares of Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider's stock valued at $1,490,239,000 after purchasing an additional 3,097,571 shares during the last quarter. Pzena Investment Management LLC lifted its stake in shares of Humana by 34.3% in the 1st quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider's stock valued at $948,614,000 after purchasing an additional 1,398,774 shares during the last quarter. Finally, State Street Corp boosted its holdings in Humana by 1.8% in the fourth quarter. State Street Corp now owns 5,462,549 shares of the insurance provider's stock worth $1,403,877,000 after purchasing an additional 97,211 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Stock Up 0.7%

Humana stock opened at $380.48 on Friday. The firm has a market cap of $45.69 billion, a price-to-earnings ratio of 36.00, a P/E/G ratio of 2.16 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The firm has a fifty day moving average price of $383.38 and a two-hundred day moving average price of $280.90.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.27 by $0.34. The company had revenue of $40.89 billion for the quarter, compared to the consensus estimate of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The firm's revenue was up 26.2% compared to the same quarter last year. During the same period last year, the business posted $6.27 earnings per share. As a group, analysts forecast that Humana Inc. will post 9.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HUM has been the topic of several analyst reports. Oppenheimer reissued an "outperform" rating and set a $405.00 target price on shares of Humana in a research report on Thursday, July 30th. Zacks Research downgraded Humana from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 11th. Jefferies Financial Group raised Humana from a "buy" rating to a "buy" rating in a report on Wednesday, May 20th. Lake Street Capital initiated coverage on Humana in a research note on Thursday, July 30th. They issued a "buy" rating on the stock. Finally, Needham & Company LLC initiated coverage on Humana in a report on Wednesday, May 20th. They issued a "buy" rating for the company. Fourteen analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $395.22.

Humana Company Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source